Ergoteles’s Cue Biopharma CUE Stock Holding History

Ergoteles’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,902	Closed	-$261K	–	1534
2022 Q3	$261K	Sell	3,902 -645	-14%	-$55.5K	0.01%	1049
2022 Q2	$340K	Buy	+4,547	New	+$532K	0.01%	1039

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's CUE Position: Q4 2022 in Review

Ergoteles sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 3,902 shares — an estimated $261K sold.

Ergoteles first reported a position in CUE in Q2 2022 and held it in 2 quarters. The position peaked at $340K in Q2 2022. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

Ergoteles reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 3,902 Cue Biopharma shares in Q4 2022, an estimated $261K.
Ergoteles first reported a position in Cue Biopharma in Q2 2022 and held it in 2 quarters.
Ergoteles's Cue Biopharma position peaked at $340K in Q2 2022.
61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.